Compare Ishares Msci Italy ETF (EWI) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Mesoblast Limited — how do they compare? Ishares Msci Italy ETF trades at $55.99 (market cap $1.14B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mesoblast Limited is the larger of the two by market cap, and Ishares Msci Italy ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Italy ETF for 52 Days and Mesoblast Limited for 14 Days on average.
| EWI | MESO | |
|---|---|---|
Market Cap | $1.14B | $1.75B |
Volume | 2,377,947 | 239,027 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.35 | $20.96 |
52-Week Low | $50.31 | $13.19 |
Typical Hold Time | 52 Days | 14 Days |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWI, the iShares MSCI Italy ETF, trades at $56.35, down 2.74% on the day, reflecting a bearish technical outlook with all moving averages signaling sell. The ETF provides exposure to Italian financials, utilities, and industrials, benefiting from EU recovery investments and sector consolidation. Recent news highlights ECB rate hikes and eurozone economic concerns, with energy-driven inflation posing headwinds.
The outlook remains cautious due to macroeconomic pressures from rising interest rates and inflation, though structural investments in Italian infrastructure offer long-term potential. Key risks include eurozone volatility and energy price shocks, while technical indicators suggest near-term weakness. Investors should weigh sector-specific strengths against broader market sentiment.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
